Telix  is buiding a state-of-the-art radiopharmaceutical production facility in Brussels South (Seneffe) in the Wallonia region of Belgium.

This facility will serve as the primary European manufacturing site for Telix’s products, aligning with the Group’s strategic objective of maintaining control and reliability of its supply chain, as well as controlling costs. It will also be an integral hub for Telix’s R&D activities, specifically in relation to the scale-up of radioisotope production.

Following the decommissioning and removal of two pre-existing cyclotrons on the site in late 2021, Telix has secured a €12.1 million ($A18.2 million) debt financing package to help fund first-stage building works, which will include the construction of a radio-pharmacy, as well as the installation of its first cyclotron, clean rooms and purification suites (Stage 1). Stage 1 works are already underway at the site.

Upon completion of Stage 1, Telix aims to have the ability to produce a wide range of medical isotopes, for use in its own commercial and clinical programs, as well as for other organizations. This will include its prostate and kidney cancer imaging agents (TLX591-CDx and TLX250-CDx) and its therapeutic candidates TLX591 and TLX250. The company has a vision and plan for the site to become a future hub for radiopharmaceutical R&D in Europe, not only for its own programs, but through collaborations with partners, including pharmaceutical and biotech companies, hospitals and universities.

To read more please visit:

Telix Radiopharmaceutical Production Facility Buildout Commences

Source: TELIX